Introduction
============

Acute kidney injury (AKI) is a common and difficult to diagnose complication among hospitalized patients with increasing incidence.

Methods
=======

A total of 665 (357 M:308 F; mean age 74 ± 14 years) emergency department (ED) patients designated for hospitalization were included in a multicenter prospective study to evaluate the utility of blood neutrophil gelatinase-associated lipocalin (NGAL) assessments as an aid in the early risk evaluation for AKI. NGAL and serum creatinine (sCr) were determined at ED presentation (T0), 6, 12, 24 and 72 hours after hospitalization. The clinical certainty of AKI was determined by ED physician (Ph) while blinded to NGAL results.

Results
=======

Preliminary diagnosis of AKI by the ED Ph occurred in 218/665 patients (33%). Final adjudicated AKI clinical diagnosis was confirmed in 49/665 patients (7%). The AUC for NGAL alone in the final diagnosis of AKI was 0.80 (± 0.07). When NGAL was added to the ED Ph\'s clinical judgement in a logistic model, the AUC was increased to 0.89 (± 0.06). The AUCs for the additional endpoints are shown in Table [1](#T1){ref-type="table"}. When the same model combining NGAL with the ED Ph\'s clinical judgement was compared to a clinical model combining T0 sCr results with the ED Ph\'s clinical judgement, the net reclassification index was 32.4%, meaning that the correction classification of AKI improved 32.4 percentage points.

                     Event   No event   AUC (95% CI)
  ------------------ ------- ---------- --------------
  Diagnosis of AKI   49      616        0.80 (0.07)
  RIFLE              25      640        0.72 (0.12)
  sCr bump           10      655        0.85 (0.10)
  Oliguria           14      651        0.81 (0.14)
  Mortality          27      638        0.76 (0.11)

Conclusion
==========

Our study demonstrated that blood NGAL measurements in patients hospitalized from the ED for critical conditions may improve the clinical diagnosis of AKI development. The routine use of NGAL in the ED may provide utility in deciding the appropriate treatment and management strategies for patients at risk for AKI development.
